Abstract
Purpose
To identify the characteristics and subtypes of depressive symptoms and explore the relationship between depressive subtypes and age among Chinese female breast cancer patients.
Method
In this cross-sectional study, 566 breast cancer patients were recruited from three tertiary comprehensive hospital in Shandong Province, China through convenient sampling from April 2013 to June 2019. Depressive symptoms were measured using the Patient Health Questionnaire-9 (PHQ-9). Data analyses included descriptive analyses, latent class analysis.
Results
There were significant differences in specific depressive symptoms by age group, but no significant difference in total scores on PHQ-9. The depressive subtypes were severe (Class 4), relatively severe (Class 3; with lower psychomotor agitation/retardation and suicidal ideation), moderate (Class 2; with higher psychomotor agitation/retardation and suicidal ideation), and mild depressive symptoms (Class 1). The distribution of depression subtypes is different in various age groups. In the 45–59 age groups, severe symptoms subtype showed the highest ratios (i.e. 50.3%).
Conclusion
This is the first study that analyses depressive symptom characteristics and identifies depressive subtypes in Chinese women with breast cancer across ages to explore symptom heterogeneity. Our findings can contribute to identifying the mechanisms behind these relationships and developing targeted interventions for patients with specific depressive subtypes.
Keywords: breast cancer, depressive symptoms, latent class analysis, heterogeneity, China, age groups
1. Introduction
In recent years improvements in the diagnosis and treatment of cancer have increased survival rates. While breast cancer, the most common type of cancer [1], has seen a significantly increasing trend in age-standardized incidence rates in Chinese women [2], the 5-year relative survival rate has increased from 73.1% to 82.0% from 2003 to 2015 [3].Owing to its untreatable nature and the common long-term exposure of patients to the illness, breast cancer tends to evoke significant psychological stress and disorders in survivors, of which depression is particularly common [4]. Two studies have shown that the prevalence of depression in cancer patients is several-fold that of the general population [5],[6], while a recent meta-analysis found that the global prevalence of depression in breast cancer patients was 32.2% [7].
Depression in female breast cancer survivors, even if it has not been properly diagnosed (e.g. the survivor has been experiencing specific depressive symptoms), may interfere with their ability to effectively cope with the disease, reduce treatment adherence, decrease quality of life, and increase the risk of recurrence and mortality [8]–[12]. Therefore, attention should be paid to female breast cancer survivors with depressive symptoms, regardless of a clinical diagnosis.
Women in different age groups may face various challenges when coping with breast cancer, resulting in different depressive symptoms by age [13],[14]. For example, younger female breast cancer patients may experience psychological stress from life-stage-related needs that occur at a younger age (e.g. employment, childcare) [15] and from perceptions regarding the fact that diagnosis and treatment may cause the partial loss of their female identity, infertility, premature menopause, and sexual dysfunction [16]–[19]. Middle-aged breast cancer female survivors normally face psychological stress from having to take care of their parents—usually in later adulthood—and from considering the potential impact of breast cancer on their children [13]. Older female adults who incur normal ageing and comorbidities (e.g. chronic diseases, age-related diseases, and geriatric problems) tend to be affected by cancer symptoms, leading to the further decline of their bodily functions [20]. Therefore, various age-related sources of stress may lead to inconsistency and heterogeneity when comparing the depressive symptoms of female breast cancer patients by age.
A few studies have analysed depressive symptoms in female breast cancer patients of different ages, but their sample had a limited age range (e.g. under 35 [21] or over 60 [22]), or their findings only compared the total scores for depressive symptoms between two age groups (e.g. ≤45 vs. 55–70 [23], ≤50 vs. >50 [24], or 18–39 vs. >39 [14]). A prior study corroborated this and concluded that, although research on the topic provided valuable evidence, researchers tend to only use the total or cut-off score of the depressive symptom scale, which conceals the heterogeneity of depressive symptoms in female cancer patients [25]. For example, even if two participants have the same total score on the depressive symptom scale, their scores may be based on different symptoms (e.g., suicidal ideation versus fatigue).
Thus, we considered latent class analysis (LCA) appropriate to explore the subtypes of breast cancer related depression while considering the potential correlation between different depressive symptoms. The LCA is a type of person-centred analytical method that focuses on distinguishing a heterogeneous population that has co-occurring symptoms to reveal potential symptomatic heterogeneity [26]. It may be helpful when trying to objectively identify heterogeneous depressive subtypes in clinical practice; doing so may provide clinicians with more information on how to develop effective prevention and intervention programmes for female breast cancer patients with different depressive subtypes.
To the best of our knowledge, no prior study to date has detailed the characteristics of depressive symptoms by multiple age groups or used depressive subtypes to explore depressive symptom heterogeneity among female breast cancer patients. Thus, this study aimed to (1) describe the characteristics of depressive symptoms, (2) identify depressive subtypes, and (3) explore the relationship between depressive subtypes and age in Chinese female breast cancer patients.
2. Methods
2.1. Study design
This study applied a cross-sectional design.
2.2. Participants
Using the convenient sampling method, we recruited female breast cancer patients by contacting three tertiary comprehensive hospitals in Shandong Province, China from April 2013 through June 2019. The inclusion criteria were as follows: (1) at least 18 years of age; (2) has been diagnosed with breast cancer; and (3) able to understand and independently answer the questionnaire. The initial sample of 573 potential participants was reduced to 566 after excluding those who did not complete a Patient Health Questionnaire-9 (PHQ-9) or indicate age data.
First, eligible patients were identified using medical records from cancer wards. Then, they were asked by the investigators, who were graduate students in the psychology department, whether or not they were willing to participate in the study. Participants who agreed gave their written informed consent before completing the questionnaire. After receiving approval from the cancer ward, we collected cancer stage data from patients' medical records. Other questionnaire items were answered through a self-report.
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and the Helsinki Declaration of 1975, as revised in 2000. The survey formed part of a research project on the mental health status of cancer patients, which was approved by the ethics committee of the School of Nursing at the Shandong University (Ethical Approval Number: 2016-R020).
2.3. Measures
We measured depressive symptoms using the Chinese version of the 9-item PHQ-9, which the American Society of Clinical Oncology recommends for the evaluation of depressive symptoms in cancer patients [27]. The PHQ-9 assesses the symptoms of participants in the 2 weeks prior to the questionnaire application [28]. It is rated on a 4-point scale ranging from 0 (not at all) to 3 (nearly every day). The nine items assess nine depressive symptoms based on the diagnostic criteria for major depressive disorder described in the DSM-IV. Participants' total score in this measure represents depressive severity, categorised as minimal (0–4), mild (5–9), moderate (10–14), and moderately severe/severe depressive symptoms (≥15). The Cronbach's alpha in this study was 0.824.
The covariate variables were age (≤35, 36–44, 45–59, and ≥60 years old), race (Han/other minorities), marital status (single/partnered), residential area (urban/rural), education level (high school or lower/above high school), occupation (retired/unemployed/employed), mode of payment of medical care (own expense/health insurance), religion (religious/not religious), and cancer stage (0/I/II/III/IV).
2.4. Statistical analysis
All descriptive analyses were performed using SPSS (version 26.0). This study compared participants' age by sociodemographic, clinical (e.g. cancer stage), and depressive characteristics (i.e. participants' mean scores for each symptom and depressive severity category based on the total PHQ-9 score).
We used a nonparametric analysis to examine the differences among the nine depressive symptoms and the depressive severity by age group. Univariate analyses, including ANOVA and Chi-square test, were used to determine differences in depressive subtypes by socio-demographic and clinical characteristics. Subsequently, analysis of variance and post-hoc tests were used to assess the differences in depressive subtypes by the nine depressive symptoms. We set the statistical significance for all analyses at P < 0.05.
We used LCA to identify the differences in depressive subtypes among female breast cancer patients, namely, whether or not there were homogeneous clusters in heterogeneous groups. We recorded the nine symptoms measured in the PHQ-9 as binary variables (1 = have depressive symptoms vs. 0 = no depressive symptoms) and included them in the model.
We tested goodness of fit for a series of models (i.e. 1–6 classes) using Mplus (version 7.4). By analysing a combination of statistical indicators—including Akaike information criterion, Bayesian information criterion, sample size adjustment BIC, Vuong-Lo-Mendell-Rubin likelihood ratio test, bootstrap likelihood ratio test, and clinical interpretability [29]—we deemed that the four-class model showed optimal fit to the data.
3. Results
3.1. Participants' characteristics
The participants had an average age of 45.6 (SD = 11.5) years; most were married (93.3%); unemployed (42.4%); and had medical insurance (95.6%). Approximately half lived in urban areas (57.6%). A majority had stage II cancer (41.3%), followed by stage IV (20.8%), III (20.7%), I (13.8%), then 0 (3.4%). The four age groups differed in many other sociodemographic and clinical characteristics, which are described in detail in Table 1.
Table 1. Sociodemographic and clinical characteristics of the total sample and different age groups (N = 566).
| Variables | Total (n = 566) | ≤35 years old (n = 95) | 36–44 years old (n = 223) | 45–59 years old (n = 151) | ≥60 years old (n = 97) | P |
| Age, x(SD)/n(%) | 45.6 (11.5) | 95 (16.8%) | 266 (47.0%) | 108 (19.1%) | 97 (17.1%) | |
| Marriage | 0.022 | |||||
| Single | 38 (6.7%) | 10 (10.5%) | 15 (6.7%) | 3 (2.0%) | 10 (10.3%) | |
| With partner | 528 (93.3%) | 85 (89.5%) | 208 (93.3%) | 148 (98.0%) | 87 (89.7%) | |
| Residence | 0.112 | |||||
| Urban area | 326 (57.6%) | 55 (57.9%) | 139 (61.7%) | 75 (49.7%) | 57 (58.8%) | |
| Rural area | 240 (42.4%) | 40 (42.1%) | 84 (38.3%) | 76 (50.3%) | 40 (41.2%) | |
| Education | <0.001 | |||||
| ≤High school | 321 (56.7%) | 31 (32.6%) | 113 (53.0%) | 101 (66.9%) | 76 (78.4%) | |
| >High school | 245 (43.3%) | 64 (67.4%) | 110 (47.0%) | 50 (33.1%) | 21 (21.6%) | |
| Occupation † | <0.001 | |||||
| Retirement | 59 (10.4%) | 1 (1.3%) | 0 (0.0%) | 13 (8.6%) | 45 (47.9%) | |
| Unemployed | 235 (41.5%) | 28 (35.4%) | 88 (39.5%) | 75 (49.7%) | 44 (46.8%) | |
| Employed | 207 (36.6%) | 50 (63.3%) | 112 (50.2%) | 40 (26.5%) | 5 (5.3%) | |
| Payment † | 0.390 | |||||
| Own expense | 15 (2.7%) | 2 (2.1%) | 9 (4.0%) | 3 (2.0%) | 1 (1.0%) | |
| With health care | 541 (95.6%) | 93 (97.9%) | 210 (94.2%) | 144 (95.4%) | 94 (99.0%) | |
| Religion | 77 (13.6%) | 14 (14.7%) | 36 (16.1%) | 16 (10.6%) | 11 (11.3%) | 0.405 |
| Race (Han) | 557 (98.4%) | 93 (97.9%) | 265 (99.6%) | 103 (95.4%) | 96 (99.0%) | 0.167 |
| Cancer stage | <0.001 | |||||
| Stage 0 | 19 (3.4%) | 2 (2.1%) | 8 (3.6%) | 1 (0.7%) | 8 (8.2%) | |
| Stage Ⅰ | 78 (13.8%) | 13 (13.7%) | 35 (15.7%) | 9 (6.0%) | 21 (21.7%) | |
| Stage Ⅱ | 234 (41.3%) | 41 (43.2%) | 111 (49.8%) | 38 (25.2%) | 44 (45.4%) | |
| Stage Ⅲ | 117 (20.7%) | 23 (24.2%) | 45 (20.2%) | 36 (23.8%) | 13 (13.4%) | |
| Stage Ⅳ | 118 (20.8%) | 16 (16.8%) | 24 (10.8%) | 67 (44.4%) | 11 (11.3%) |
Note: † Indicates that the numbers/percentages may not add up to the total, due to missing data.
3.2. Differences in depressive symptoms among female breast cancer patients by age
Of all participants, 22.8% had moderate to severe depressive symptoms (i.e. PHQ-9 scores ≥10). The percentage for moderately severe/severe depressive symptoms (i.e. PHQ-9 scores ≥15) was 2.1% for participants aged ≥35, 9.4% for those aged 36–44, 5.3% for those aged 45–59, and 9.3% for those aged ≥60 (Figure 1).
Figure 1. The severity of depressive symptoms varies among breast cancer patients of different ages according to the PHQ-9 cutoff scores. Minimal depression (PHQ-9 score 0–4), mild (5–9), moderate (10–14) and moderately severe/severe (≥15). PHQ-9, Patient Health Questionnaire-9.
There were significant differences were found for the following symptoms: sadness, poor concentration, psychomotor agitation/retardation, and suicidal ideation. In addition, participants of different age groups differed in the severity of depressive symptoms (see Table 2).
Table 2. Characteristics of depression in different age groups (N = 566).
| M (QL;QU)/n(%) | Total (n = 566) | ≤35 years | 36–44 years | 45–59 years | ≥60 years | P |
| Anhedonia | 1.0 (0.0;1.0) | 1.0 (0.0;1.0) | 1.0 (0.0;1.0) | 1.0 (1.0;1.0) | 1.0 (0.0;1.0) | 0.095 |
| Sadness | 1.0 (0.0;1.0) | 1.0 (0.0;1.0) | 1.0 (0.0;1.0) | 1.0 (1.0;2.0) | 1.0 (0.0;1.0) | 0.001 |
| Sleep disturbances | 1.0 (1.0;1.0) | 1.0 (1.0;1.0) | 1.0 (0.0;1.0) | 1.0 (1.0;2.0) | 1.0 (0.0;2.0) | 0.328 |
| Fatigue | 1.0 (1.0;1.0) | 1.0 (1.0;1.0) | 1.0 (1.0;2.0) | 1.0 (1.0;1.0) | 1.0 (0.0;1.0) | 0.286 |
| Appetite disturbances | 1.0 (0.0;1.0) | 1.0 (0.0;1.0) | 1.0 (0.0;1.0) | 1.0 (1.0;1.0) | 1.0 (0.0;1.0) | 0.178 |
| Guilt or worthlessness | 1.0 (0.0;1.0) | 1.0 (0.0;1.0) | 1.0 (0.0;1.0) | 1.0 (0.0;1.0) | 0.0 (0.0;1.0) | 0.064 |
| Poor concentration | 0.0 (0.0;1.0) | 1.0 (0.0;1.0) | 1.0 (0.0;1.0) | 0.0 (0.0;1.0) | 0.0 (0.0;1.0) | 0.003 |
| Psychomotor agitation or retardation | 0.0 (0.0;1.0) | 0.0 (0.0;1.0) | 0.0 (0.0;1.0) | 0.0 (0.0;1.0) | 0.0 (0.0;1.0) | 0.003 |
| Suicidal ideation | 0.0 (0.0;0.25) | 0.0 (0.0;0.0) | 0.0 (0.0;1.0) | 0.0 (0.0;0.0) | 0.0 (0.0;0.5) | <0.001 |
| PHQ total | 7.0 (4.0;9.0) | 7.0 (4.0;9.0) | 7.0 (4.0;10.0) | 7.0 (4.0;9.0) | 5.0 (2.0;9.0) | 0.034 |
| PHQ average | 0.8 (0.4;1.0) | 0.8 (0.4;1.0) | 0.8 (0.4;1.1) | 0.8 (0.4;1.0) | 0.6 (0.2;1.0) | 0.034 |
| PHQ-9 (≥5) | 384 (67.8%) | 68 (71.6%) | 153 (68.6%) | 112 (74.2%) | 51 (52.6%) | 0.003 |
| PHQ (≥10) | 129 (22.8%) | 17 (17.9%) | 63 (28.3%) | 29 (19.2%) | 20 (20.6%) | 0.092 |
| PHQ degree | 0.001 | |||||
| Minimal | 182 (32.2%) | 27 (28.4%) | 70 (31.4%) | 39 (25.8%) | 46 (47.4%) | |
| Mild | 255 (45.1%) | 51 (53.7%) | 90 (40.4%) | 83 (55.0%) | 31 (32.0%) | |
| Moderate | 89 (15.7%) | 15 (15.8%) | 42 (18.8%) | 21 (13.9%) | 11 (11.3%) | |
| Moderately severe/severe | 40 (7.1%) | 2 (2.1%) | 21 (9.4%) | 8 (5.3%) | 9 (9.3%) |
3.3. Heterogeneity and depressive subtypes in female breast cancer patients
Considering goodness of fit and clinical interpretability, we determined four depressive subtypes: Class 1, 2, 3, and 4; these accounted for 27%, 16%, 30%, and 27% of all participants, respectively (Table 3). Figure 2 and Table 4 show the probability and descriptive data of participants' scores for the nine depressive symptoms in the PHQ-9 by depressive subtype. Class 4 represented the highest probability (i.e. probability of experiencing a symptom) and score for all nine symptoms; thus, it was named the severe symptoms group; Class 3 represented a relatively high probability and score for all symptoms—except for psychomotor agitation/retardation and suicidal ideation, which showed lower levels—and thus, it was named the relatively severe symptoms group; Class 2 represented a medium probability and score for all nine symptoms—except for psychomotor agitation/retardation and suicidal ideation, which showed higher levels—and thus, it was named the moderate symptoms group; and Class 1 represented the lowest probability and score for all nine symptoms—except for psychomotor agitation/retardation, which showed higher levels—and therefore, it was named the mild symptoms group. There were significant differences between these four classes and the nine depressive symptoms assessed using the PHQ-9 (Table 4).
Table 3. Model fit indices derived from latent class analysis on models with 1–6 classes.
| Model | K | Log (L) | AIC | BIC | aBIC | entropy | LMR | BLRT | Class probability |
| 1 | 9 | −3096.85 | 6211.70 | 6250.75 | 6222.18 | ||||
| 2 | 19 | −2540.85 | 5119.70 | 5202.14 | 5141.82 | 0.86 | 0.00 | 0.00 | 368/198(0.65/0.35) |
| 3 | 29 | −2441.40 | 4940.80 | 5066.62 | 4974.56 | 0.82 | 0.00 | 0.00 | 152/259/155(0.27/0.46/0.27) |
| 4 | 39 | −2402.15 | 4882.30 | 5051.51 | 4927.70 | 0.78 | 0.02 | 0.00 | 155/91/170/150(0.27/0.16/0.30/0.27) |
| 5 | 49 | −2368.00 | 4833.98 | 5046.57 | 4891.02 | 0.80 | 0.002 | 0.00 | 49/141/148/130/98(0.09/0.25/0.26/0.23/0.17) |
| 6 | 59 | −2354.61 | 4827.22 | 5083.20 | 4895.90 | 0.81 | 0.46 | 0.09 | 107/38/146/52/77/146(0.19/0.07/0.26/0.09/0.14/0.26) |
Note: Abbreviations: AIC, Akaike information criterion; BIC, Bayesian information criterion; aBIC, sample size adjusted BIC; LMR, Vuong-Lo-Mendell-Rubin likelihood ratio test. BLRT, bootstrapped likelihood ratio test; Bold values indicates that a four-class model was determined as optimal one.
Figure 2. The five-class model and probability of nine depressive symptoms within each class (n = 566). Class 4: severe symptoms group; Class 3: relatively severe group (with lower concentration, psychomotor agitation/retardation and suicidal ideation); Class 2: moderate symptoms group (with higher poor concentration, psychomotor agitation/retardation and suicidal ideation); Class 1: mild symptoms group.
Table 4. The descriptive scores of nine depressive symptoms, M(SD).
| Items | Class 4 (n = 150) | Class 3 (n = 170) | Class 2 (n = 91) | Class 1 (n = 155) | F | Posthoc comparisons |
| Anhedonia | 1.40 (0.63) | 1.19 (0.57) | 0.86 (0.68) | 0.26 (0.52) | 109.39* | c4>c3>c2>c1 |
| Sadness | 1.41 (0.65) | 1.42 (1.62) | 0.75 (0.59) | 0.19 (0.43) | 53.55* | c3≈c4>c2>c1 |
| Sleep disturbances | 1.49 (0.70) | 1.31 (1.03) | 1.04 (0.87) | 0.43 (0.62) | 49.75* | c4>c3>c2>c1 |
| Fatigue | 1.59 (0.71) | 1.20 (0.53) | 1.13 (0.70) | 0.49 (0.70) | 73.87* | c4>c3≈c2>c1 |
| Appetite disturbances | 1.37 (0.68) | 1.06 (0.81) | 0.88 (0.73) | 0.21 (0.43) | 81.11* | c4>c3>c2>c1 |
| Guilt or worthlessness | 1.50 (0.67) | 0.76 (0.67) | 0.34 (0.67) | 0.07 (0.26) | 163.33* | c4>c3>c2>c1 |
| Poor concentration | 1.35 (0.64) | 0.34 (0.61) | 1.01 (0.71) | 0.07 (0.26) | 159.56* | c4>c2>c3>c1 |
| Psychomotor agitation or retardation | 1.30 (0.69) | 0.00 (0.00) | 0.81 (0.65) | 0.04 (0.22) | 288.45* | c4>c2>c1≈c3 |
| Suicidal ideation | 0.89 (0.73) | 0.07 (0.30) | 0.31 (0.61) | 0.03 (0.16) | 102.77* | c4>c2>c3≈c1 |
| PHQ-9 total score | 12.29 (3.85) | 7.36 (2.81) | 7.13 (2.29) | 1.79 (1.47) | 362.34* | c4>c3≈c2>c1 |
Note: *P < 0.01. Class 4: severe symptoms group; Class 3: relatively severe group (with lower concentration, psychomotor agitation/retardation and suicidal ideation); Class 2: moderate symptoms group (with higher poor concentration, psychomotor agitation/retardation and suicidal ideation); Class 1: mild symptoms group.
Participants' depressive subtype distribution by age is presented in Figure 3. In the ≤35 age group, all four classes showed similar ratios (Class 1–4 were 28.4%, 24.2%, 24.2%, and 23.2%, respectively). In the 36–44 age group, 33.2% of the participants were categorized in Class 3, which was the highest proportion. In the 45–59 age groups, Class 4 showed the highest ratios (i.e. 50.3%). In the ≥60 age group, more than 50 percent of participants were categorized in the milder depressive subtypes, with Class 1 and 2 accounting for 12.4% percent and 42.3%, respectively.
Figure 3. The subtypes distribution in the four stage of age. Class 4: severe symptoms group; Class 3: relatively severe group (with lower concentration, psychomotor agitation/retardation and suicidal ideation); Class 2: moderate symptoms group (with higher poor concentration, psychomotor agitation/retardation and suicidal ideation); Class 1: mild symptoms group.
4. Discussion
This study aimed to analyse the depressive characteristics of breast cancer patients in different adult age groups. We were able to identify four latent depressive subtypes, and their distribution differed by age group. To the best of our knowledge, this is the first study to analyse and use potential depressive subtypes to explore the heterogeneity of depressive symptoms across various adult age groups in female breast cancer patients.
The incidence of moderate to severe depressive symptoms in our sample was 22.8%; this number was similar to that reported in a previous study, which showed that such incidence in female breast cancer patients was 2–3 times higher than that in the general population [14]. Additionally, our analyses highlighted differences in single-symptom expression by age—specifically, such differences were observed for sadness, poor concentration, psychomotor agitation/retardation, and suicidal ideation. This result is supported by that of a previous study, which reported on individuals' symptomatology heterogeneity [25]. Another study showed that the age-related difference in depressive symptoms among female cancer patients is due to the impact of cancer and its treatment on specific areas of women's life (e.g. work, sex, and entertainment) [15]. Therefore, stakeholders involved in diminishing the risk of depression in breast cancer patients should focus on depressive symptom differences by age. Moreover, in-depth analyses on the causes of such age-related differences must be conducted and interventions aimed at groups characterised by specific depressive subtypes must be applied to reduce the risk of depression.
We were able to identify four depressive subtypes: severe (Class 4), relatively severe (Class 3), moderate (Class 2), and mild depressive symptoms (Class 1). Differences in the severe, moderate, and mild groups were mainly because of depressive symptom severity, whereas the relatively severe group differed from the other three primarily owing to the presence of severe physio-somatic symptoms alongside lower psychomotor agitation/retardation and suicidal ideation. This suggests that, upon the application of LCA, both symptom characteristics and severity were important variables in determining depressive subtypes. Our results are somewhat consistent with those of previous studies showing symptomatic severity to be a crucial discriminating aspect of depressive subtypes [30],[31]. The relatively severe group with lower psychomotor agitation/retardation and suicidal ideation was discovered in this research, and it was also the most common subtype in our sample. A study that promoted a factorial analysis on the items of the PHQ-9 pointed out that the items on poor concentration and psychomotor agitation/retardation may neither belong to an affective-cognitive nor a somatic component [32]. This item contains two contradictory characteristics of psychological and cannot be clearly classified as one of the factors, which also confirms the heterogeneity of depressive symptoms. Previous studies have suggested that suicidal ideation in breast cancer patients is particularly linked to genetic characteristics (brain-derived neurotrophic factor methylation, BDNF met allele) [33]. Along with another study [34], these findings and our results suggest that depressive symptoms do not have a single structure but are comprised of different subtypes that seem to have different pathophysiological basis.
The latent depressive subtypes we observed showed different distributions by age group. Specifically, patients aged 45–59 were more likely to have severe depressive subtype; those aged 36–44 were more likely to have relatively severe depressive subtype; those over 60 were more likely to have moderate symptoms group; and those under 35 were more likely to have mild depressive subtype. After a literature review, it is evident why female breast cancer patients aged 36 and over showed a greater tendency to experience relatively severe depressive symptoms. A study showed that perimenopausal women over 40 may suffer from poorer sleep quality and greater mood problems owing to fluctuating hormone levels, both of which are also depressive symptoms [35]. Another study revealed that breast cancer treatment may lead to menopause in women, while the stress caused by cancer and its treatment may influence depressive symptom severity [36]. When combined with the social responsibilities that female breast cancer survivors tend to have, such as caring for parents and children, the situation can lead them to experience the most severe depressive symptoms [13]. Therefore, stakeholders in the well-being of female breast cancer patients should place greater emphasis on their psychological status based on age. In clinical practice, the different depressive subtypes—and their relationships with specific age groups—described in this study may help stakeholders (e.g. physicians, psychologists, nurses) more accurately identify groups with similar symptoms across the cancer population. Greater accuracy could thereby facilitate the development and application of appropriate group interventions aimed at dealing with similar depressive symptoms.
Despite the contributions highlighted above, this study had several limitations. First, the reliability and validity of individual symptom measurement tools—including those of the PHQ-9, which was utilised in this study—remain imprecise. Nonetheless, one advantage of the PHQ-9 is that all entries have the same response categories, which theoretically does not affect the comparability between different symptoms [33]. Future research should investigate scales for specific symptoms (e.g. suicidal ideation), such as the Suicide Severity Scale to assess suicidal behaviour [37]. Second, although the LCA assigns individuals to subtypes according to probability and evaluates the goodness of fit of different models based on statistical criteria, one study has shown that subjectivity in this procedure still exists [29]; therefore, we cannot exclude type I errors (i.e. false positives). Third, we applied convenient sampling and utilised a cross-sectional design, which are methodologies that limit the generalizability of our findings; thus, future research should consider larger populations, stratified random sampling, and a longitudinal design when analysing depressive symptoms in female breast cancer patients.
5. Conclusions
This study described the characteristics of depressive symptoms in Chinese female breast cancer patients across different ages and identified four depressive subtypes. Our results support the heterogeneity of depressive symptoms; thus, we provide data on how to identify individual symptoms in different age groups and patients with similar symptoms characteristics. We hope that this study helps in identifying the potential mechanisms behind these relationships and develop targeted interventions for patients with a specific depressive subtype.
Acknowledgments
This work was supported by the Natural Science Foundation of Shandong Province [Grant Number ZR2017MC070]. We are thankful for the generous contributions of the research participants and the staff who assisted with data collection during the study.
Footnotes
Conflict of interest: All authors declare no conflicts of interest in this paper.
References
- 1.Yap YS, Lu YS, Tamura K, et al. Insights Into Breast Cancer in the East vs the West: A Review. JAMA Oncol. 2019;5:1489–1496. doi: 10.1001/jamaoncol.2019.0620. [DOI] [PubMed] [Google Scholar]
- 2.Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–132. doi: 10.3322/caac.21338. [DOI] [PubMed] [Google Scholar]
- 3.Zeng H, Chen W, Zheng R, et al. Changing cancer survival in China during 2003–15: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health. 2018;6:e555–e567. doi: 10.1016/S2214-109X(18)30127-X. [DOI] [PubMed] [Google Scholar]
- 4.Gold SM, Kohler-Forsberg O, Moss-Morris R, et al. Comorbid depression in medical diseases. Nat Rev Dis Primers. 2020;6:69. doi: 10.1038/s41572-020-0200-2. [DOI] [PubMed] [Google Scholar]
- 5.Krebber AM, Buffart LM, Kleijn G, et al. Prevalence of depression in cancer patients: a meta-analysis of diagnostic interviews and self-report instruments. Psychooncology. 2014;23:121–130. doi: 10.1002/pon.3409. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Pratt LA, Brody DJ. Depression in the U.S. household population, 2009–2012. NCHS Data Brief. 2014:1–8. [PubMed] [Google Scholar]
- 7.Pilevarzadeh M, Amirshahi M, Afsargharehbagh R, et al. Global prevalence of depression among breast cancer patients: a systematic review and meta-analysis. Breast Cancer Res Treat. 2019;176:519–533. doi: 10.1007/s10549-019-05271-3. [DOI] [PubMed] [Google Scholar]
- 8.Walker J, Hansen CH, Martin P, et al. Prevalence, associations, and adequacy of treatment of major depression in patients with cancer: a cross-sectional analysis of routinely collected clinical data. Lancet Psychiatry. 2014;1:343–350. doi: 10.1016/S2215-0366(14)70313-X. [DOI] [PubMed] [Google Scholar]
- 9.Mausbach BT, Schwab RB, Irwin SA. Depression as a predictor of adherence to adjuvant endocrine therapy (AET) in women with breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat. 2015;152:239–246. doi: 10.1007/s10549-015-3471-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Markovitz LC, Drysdale NJ, Bettencourt BA. The relationship between risk factors and medication adherence among breast cancer survivors: What explanatory role might depression play? Psychooncology. 2017;26:2294–2299. doi: 10.1002/pon.4362. [DOI] [PubMed] [Google Scholar]
- 11.Chan CM, Wan Ahmad WA, Yusof MM, et al. Effects of depression and anxiety on mortality in a mixed cancer group: a longitudinal approach using standardised diagnostic interviews. Psychooncology. 2015;24:718–725. doi: 10.1002/pon.3714. [DOI] [PubMed] [Google Scholar]
- 12.Grotmol KS, Lie HC, Hjermstad MJ, et al. Depression-A Major Contributor to Poor Quality of Life in Patients With Advanced Cancer. J Pain Symptom Manage. 2017;54:889–897. doi: 10.1016/j.jpainsymman.2017.04.010. [DOI] [PubMed] [Google Scholar]
- 13.Hasson-Ohayon I, Goldzweig G, Dorfman C, et al. Hope and social support utilisation among different age groups of women with breast cancer and their spouses. Psychol Health. 2014;29:1303–1319. doi: 10.1080/08870446.2014.929686. [DOI] [PubMed] [Google Scholar]
- 14.Naik H, Leung B, Laskin J, et al. Emotional distress and psychosocial needs in patients with breast cancer in British Columbia: younger versus older adults. Breast Cancer Res Treat. 2020;179:471–477. doi: 10.1007/s10549-019-05468-6. [DOI] [PubMed] [Google Scholar]
- 15.Avis NE, Levine B, Naughton MJ, et al. Explaining age-related differences in depression following breast cancer diagnosis and treatment. Breast Cancer Res Treat. 2012;136:581–591. doi: 10.1007/s10549-012-2277-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Vazquez D, Rosenberg S, Gelber S, et al. Posttraumatic stress in breast cancer survivors diagnosed at a young age. Psychooncology. 2020;29:1312–1320. doi: 10.1002/pon.5438. [DOI] [PubMed] [Google Scholar]
- 17.Ruddy KJ, Partridge AH. The unique reproductive concerns of young women with breast cancer. Adv Exp Med Biol. 2012;732:77–87. doi: 10.1007/978-94-007-2492-1_6. [DOI] [PubMed] [Google Scholar]
- 18.Gomez-Campelo P, Bragado-Alvarez C, Hernandez-Lloreda MJ. Psychological distress in women with breast and gynecological cancer treated with radical surgery. Psychooncology. 2014;23:459–466. doi: 10.1002/pon.3439. [DOI] [PubMed] [Google Scholar]
- 19.Rosenberg SM, Tamimi RM, Gelber S, et al. Treatment-related amenorrhea and sexual functioning in young breast cancer survivors. Cancer. 2014;120:2264–2271. doi: 10.1002/cncr.28738. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Fontein DB, de Glas NA, Duijm M, et al. Age and the effect of physical activity on breast cancer survival: A systematic review. Cancer Treat Rev. 2013;39:958–965. doi: 10.1016/j.ctrv.2013.03.008. [DOI] [PubMed] [Google Scholar]
- 21.Lan B, Jiang S, Li T, et al. Depression, anxiety, and their associated factors among Chinese early breast cancer in women under 35 years of age: A cross sectional study. Curr Probl Cancer. 2020;4:100558. doi: 10.1016/j.currproblcancer.2020.100558. [DOI] [PubMed] [Google Scholar]
- 22.Mandelblatt JS, Zhai W, Ahn J, et al. Symptom burden among older breast cancer survivors: The Thinking and Living With Cancer (TLC) study. Cancer. 2020;126:1183–1192. doi: 10.1002/cncr.32663. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Champion VL, Wagner LI, Monahan PO, et al. Comparison of younger and older breast cancer survivors and age-matched controls on specific and overall quality of life domains. Cancer. 2014;120:2237–2246. doi: 10.1002/cncr.28737. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Sheppard VB, Harper FW, Davis K, et al. The importance of contextual factors and age in association with anxiety and depression in Black breast cancer patients. Psychooncology. 2014;23:143–150. doi: 10.1002/pon.3382. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Fried EI, Nesse RM, Zivin K, et al. Depression is more than the sum score of its parts: individual DSM symptoms have different risk factors. Psychol Med. 2014;44:2067–2076. doi: 10.1017/S0033291713002900. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Ten Have M, Lamers F, Wardenaar K, et al. The identification of symptom-based subtypes of depression: A nationally representative cohort study. J Affect Disord. 2016;190:395–406. doi: 10.1016/j.jad.2015.10.040. [DOI] [PubMed] [Google Scholar]
- 27.Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606–613. doi: 10.1046/j.1525-1497.2001.016009606.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Andersen BL, DeRubeis RJ, Berman BS, et al. Screening, assessment, and care of anxiety and depressive symptoms in adults with cancer: an American Society of Clinical Oncology guideline adaptation. J Clin Oncol. 2014;32:1605–1619. doi: 10.1200/JCO.2013.52.4611. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Nylund KL, Asparouhov T, Muthén BO. Deciding on the Number of Classes in Latent Class Analysis and Growth Mixture Modeling: A Monte Carlo Simulation Study. Struct Equ Modeling. 2007;14:535–569. [Google Scholar]
- 30.Zhu L, Ranchor AV, van der Lee M, et al. Subtypes of depression in cancer patients: an empirically driven approach. Support Care Cancer. 2016;24:1387–1396. doi: 10.1007/s00520-015-2919-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Li J, Zhang H, Shao D, et al. Depressive Symptom Clusters and Their Relationships With Anxiety and Posttraumatic Stress Disorder Symptoms in Patients With Cancer: The Use of Latent Class Analysis. Cancer Nurs. 2019;42:388–395. doi: 10.1097/NCC.0000000000000624. [DOI] [PubMed] [Google Scholar]
- 32.Hinz A, Mehnert A, Kocalevent RD, et al. Assessment of depression severity with the PHQ-9 in cancer patients and in the general population. BMC Psychiatry. 2016;16:22. doi: 10.1186/s12888-016-0728-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Kim JM, Jang JE, Stewart R, et al. Determinants of suicidal ideation in patients with breast cancer. Psychooncology. 2013;22:2848–2856. doi: 10.1002/pon.3367. [DOI] [PubMed] [Google Scholar]
- 34.Dooley LN, Ganz PA, Cole SW, et al. Val66Met BDNF polymorphism as a vulnerability factor for inflammation-associated depressive symptoms in women with breast cancer. J Affect Disord. 2016;197:43–50. doi: 10.1016/j.jad.2016.02.059. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Carpenter JS, Igega CM, Otte JL, et al. Somatosensory amplification and menopausal symptoms in breast cancer survivors and midlife women. Maturitas. 2014;78:51–55. doi: 10.1016/j.maturitas.2014.02.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Howard-Anderson J, Ganz PA, Bower JE, et al. Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. J Natl Cancer Inst. 2012;104:386–405. doi: 10.1093/jnci/djr541. [DOI] [PubMed] [Google Scholar]
- 37.Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168:1266–1277. doi: 10.1176/appi.ajp.2011.10111704. [DOI] [PMC free article] [PubMed] [Google Scholar]